08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

BSD-2000 Hyperthermia System: Phase I/II started

BSD began the open-label, German Phase I/II HyRec trial to evaluate the BSD-2000 Hyperthermia System in combination with 5-fluorouracil (5-FU) and oxaliplatin chemotherapy and radiotherapy in about 59 patients. BSD-2000 has Humanitarian Device Exemption (HDE)...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Clinical News

BSD-2000 Hyperthermia System regulatory update

The National Comprehensive Cancer Network (NCCN) updated its clinical practice guidelines in oncology to include hyperthermia and chemotherapy as a recommended treatment for high-risk soft tissue sarcoma (STS) based on data from BSD's Phase III...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

BSD-2000 Hyperthermia System: Phase III data

Data from an international Phase III trial in 341 patients with localized, high-risk STS showed that the BSD-2000 Hyperthermia System plus neoadjuvant chemotherapy with etoposide, ifosfamide and doxorubicin significantly reduced local tumor progression at 2...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Clinical News

BSD-2000: Phase III started

BSD began an international Phase III trial to evaluate gemcitabine with or without the BSD-2000 Hyperthermia System in pancreatic cancer patients with surgical tumor resection. BSD Medical Corp. (NASDAQ:BSDM), Salt Lake City, Utah   Product: BSD-2000...